# Centene Corporation  Share Price Target ‘$89.60’, now 21.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/centene-corporation-share-price-target-89.60-now-21.4-upside-potential/4121154220
- Published: 2024-05-01T13:59:37+01:00
- Author: Charlotte Edwards

**Centene Corporation** with ticker code (CNC) have now 15 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The target price High/Low 
ranges between $110.00 and $76.00 and has a mean share price target at $89.60. (
at the time of writing). Given that the stocks previous close was at $73.83 this
would imply there is now a potential upside of 21.4%. The 50 day MA is $76.12 and
the 200 moving average now moves to $72.34. The company has a market cap of 38.99B.
The stock price for the company is currently $73.06 USD

 The potential market cap would be $47,316,890,452 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/
E ratio of 14.41, revenue per share of $264.74 and a 3.67% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-
sponsored and commercial healthcare programs, focusing on under-insured and uninsured
individuals. It provides a range of managed healthcare products and services, primarily
through Medicaid, Medicare, and commercial products. Its segments include Medicaid,
Medicare, Commercial and Other. It offers Medicaid and Medicare members (including
Medicare Prescription Drug Plans) as well as individuals and families served by 
the Health Insurance Marketplace and the TRICARE program. It also contracts with
other healthcare and commercial organizations to provide a variety of specialty 
services focused on treating the whole person. Medicaid program provides health 
insurance to low-income families and individuals with disabilities. Medicare is 
a federal health insurance program for people ages 65 and over, which also covers
people under 65 with certain disabilities and people with end-stage renal diseases.

Share on: